No respite for RemeGen as problems and losses pile up
The developer of innovative drugs has sustained a series of blows to its finances, corporate partnerships, management team and star product, leaving investors jittery Key Takeaways: Despite rising revenue, RemeGen…
Earnings blow for CSPC Pharma as the state drives a hard bargain
The generic drugs giant has warned of a 26% slide in annual profits after China’s national healthcare system imposed big price cuts on qualifying medicines Key Takeaways: CSPC Pharma…
As Covid drug cash dwindles, Vigonvita targets new remedies
A Chinese biotech that made a name for itself by co-developing an anti-Covid drug has filed for a stock market listing to fund research into tackling other conditions Key Takeaways:…
AstraZeneca could face limited fallout from Chinese tax probe
The drugs giant and one of its top executives are being investigated over business tactics in China, but a potential fine for one alleged offence would not break the bank…
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
Hong Kong shareholders have foiled plans by Fosun Pharma to take its biologics subsidiary off the stock market at half the IPO price Key Takeaways: Fosun Pharma has pledged to…
WuXi Biologics sells vaccine plant as new U.S. law looms
The Chinese drug services giant built an Irish factory to produce vaccines for Merck, but has now opted to sell the plant to the U.S.-based multinational for $500 million Key…
Cancer drug maker Genfleet joins Hong Kong IPO influx
The biotech can boast a long list of big-name backers and has brought a promising drug to the market with its partner Innovent, but its cash reserves are dwindling Key…
Recent Articles
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- Sichuan Biokin chases Hong Kong listing after BSM drug deal
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
